405090-65-5

Basic information

• Product Name: 3-IodoMethyl-piperidine-1-carboxylic acid benzyl ester
• Synonyms: 3-IodoMethyl-piperidine-1-carboxylic acid benzyl ester;benzyl 3-(iodomethyl)piperidine-1-carboxylate
• CAS NO: 405090-65-5
• Molecular Formula: C₁₄H₁₈INO₂
• Molecular Weight: 359.20269
• Mol File: 405090-65-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-IodoMethyl-piperidine-1-carboxylic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IodoMethyl-piperidine-1-carboxylic acid benzyl ester(405090-65-5)
• EPA Substance Registry System: 3-IodoMethyl-piperidine-1-carboxylic acid benzyl ester(405090-65-5)

Safety Data

• Hazardous Substances Data: 405090-65-5(Hazardous Substances Data)

Upstream product

• 39945-51-2 benzyl 3-(hydroxymethyl)-1-piperidinecarboxylate 
• 4606-65-9 3-(hydroxymethy)piperidine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 820231-91-2 3-(2-oxo-2H-pyridin-1-ylmethyl)piperidine-1-carboxylic acid benzyl ester 
• 405089-80-7 3-(4-Trifluoromethoxy-phenoxymethyl)-piperidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

10-Substituted Cytisine Derivatives and Methods of Use Thereof

The present invention relates to substituted cytisine compounds that are useful in treating diseases impacted by a nicotinic ACh receptor. One aspect of the invention relates to 10-substituted cytisine compounds. In certain instances, the cytisine is subs

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.